# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹341 Cr** consolidated Q2 FY'26 · **₹715 Cr** consolidated H1 FY'26 * **EBITDA:** **₹67 Cr** Q2 FY'26 (19% margin) · **₹131 Cr** H1 FY'26 (18% margin) * **PAT:** **₹37 Cr** Q2 FY'26 · **₹74 Cr** H1 FY'26 (10% margin) ## B. Revenue & Growth * **Sequential Revenue Dip, Margin Upside:** Q2 revenue declined modestly from Q1, but EBITDA margin expanded significantly, reflecting **operational leverage and cost discipline**. * **Strong H1 Profit Conversion:** Maintained stable profitability despite revenue fluctuation, with **10% PAT margin** sustained over H1. ## C. Balance Sheet * **Prudent Financial Position:** Remains **zero-debt** on a stand-alone basis, supported by robust cash reserves and efficient working capital management. --- # 2. Volume & Operational Metrics ## A. Key Figures * **Total Operational Volumes:** **26,165 MT** Q2 FY'26 (flat YoY), comprising **7,685 MT amines**, **8,374 MT amines derivatives**, **10,107 MT specialty chemicals** * **Plant Utilization:** **80–85%** methylamines (Unit 4), **30–35%** butylamine, **20–30%** dimethyl carbonate & PG, **very low** at Balaji Specialty * **Working Capital Cycle:** **60–90 days** (normal range) ## B. Production Volumes * **Stable Aggregate Output:** Total volumes held flat YoY, reflecting balanced performance across amines, derivatives, and specialty chemicals despite individual constraints. * **Acetonitrile Output Limited:** Production remains cyclical due to ongoing plant modifications, operating on a **10-day shutdown / 20-day production** cycle. ## C. Plant Utilization * **Underutilization Across Key Units:** Methylamines near mid-teens below capacity; butylamine and battery-linked chemicals (DMC, PG) operate below 35% due to client-side delays and market conditions. * **Balaji Specialty Disruption:** Very low utilization persists due to brownfield expansion, with operations active only **15–20 days per month** on shared site. ## D. Working Capital * **Healthy Working Capital Management:** Cycle remains within historical norms, with no signs of inventory pile-up or receivables stress post-demand normalization. --- # 3. Capacity & Project Progress ## A. Key Figures * **New Capacity:** **60 TPD** operational ramp-up expected to significantly boost domestic and export supply * **Acetonitrile Production:** Currently running at **5–10% capacity** ahead of technology upgrade ## B. New Commissioning * **Near-Term Commissioning:** DME and N-methylmorpholine plants targeted for completion by **end of current quarter**, with DMC follow-on in early next quarter. * **Regulatory Progress:** Valve approval secured; cylinder permission expected within **2–3 weeks**, enabling aerosol customer sampling post-commissioning. * **Approvals Imminent:** Dimethyl ether PESO approvals and blending applications expected to be finalized shortly, supporting commissioning **before quarter-end**. * **FY25–27 Project Pipeline:** DME plant (Unit 4) and N-methylmorpholine projects on track for FY25–26, while acetonitrile expansion (new process) slated for FY26–27. ## C. Expansion Timeline * **Brownfield & Greenfield Momentum:** Unit 1 EDA expansion scheduled for **September 2026**, while Unit 2 greenfield project at Chincholi in equipment installation phase for **December 2026** commissioning. * **Phased Ramp-Up:** Unit 1 full capacity expected at start of next fiscal year; Unit 2 production to begin in **Q2 of next FY**, with 1–2 plants coming online. * **Technology Upgrade:** Acetonitrile high-purity, low-cost manufacturing upgrade on track for **Q1 next FY** full operation. --- # 4. Product & Segment Performance ## A. Key Figures * Subsidiary Revenue (H1): ~₹70 Cr (±₹1 Cr) * **EDA Capacity Allocation:** **15,000–16,000 tpa** for value-added products · **6,000 tpa** available for sale (post brownfield) · **22,000 tpa** currently sold * **DMC Production Capacity Utilization:** **20%** (non-battery markets) ## B. Battery-Grade Chemicals * **Limited Commercial Traction:** Battery-grade DMC and NMP remain in trial and pre-ramp-up phase, with **no confirmed customer approvals** or end-user demand despite product readiness. * **Brownfield Expansion Critical:** Full financial benefits from the Balaji Specialty Unit 1 project hinge on completion of modifications enabling large-scale production of **TETA, TEPA, DETA, and PIP**. * **Niche Export Activity:** Small-scale seed marketing and **1–2 ISO tank exports per month** ongoing amid constrained capacity. ## C. Pharma & Agro Demand * **Pharma PG Delayed:** Production of pharma-grade propylene glycol awaits regulatory license; technical and food grades currently supplied. * **Demand Recovery Underway:** Offtake from pharma and agro segments is **slowly improving** after recent weakness, with return to normalcy expected in coming quarters. * **Long-Term Growth Catalyst:** Emerging demand linked to **new GLP drugs**, with **significant volume uptake anticipated by FY28–29**. ## D. Specialty Products * **Strategic Expansion Underway:** **₹750 Cr mega project** by Balaji Specialty Chemicals for hydrogen cyanide, sodium cyanide, and EDTA derivatives has **mega project status** under Maharashtra’s incentive scheme. * **Margin Advantage Confirmed:** Process innovation in **acetonitrile production** has enhanced margins, providing a competitive edge over domestic peers. * **Import Substitution Focus:** Capacity ramp-up in electronic-grade DMC and pharma-grade PG is key to capturing domestic market share and boosting future earnings. --- # 5. Supply & Cost Drivers ## A. Key Figures * **Acetonitrile Price:** **₹140–150/kg** (stable last 6 months) * **Green Energy Mix:** **80%** of manufacturing power from solar energy * **DME Demand:** **30,000–35,000 tons** in aerosol industry ## B. Raw Material Prices * **Stable Input Costs:** Acetonitrile prices have remained range-bound for six months, supporting cost predictability despite volatility in methanol and ammonia. * **Inventory Management:** Company maintains inventory levels amid intermittent production, leveraging lower-cost raw materials already in the pipeline to shield margins. ## C. Green Energy Mix * **Sustainable Production:** Ethanolamine manufacturing exclusively via ethylene oxide route, enabling alignment with green chemistry goals and **80% solar-powered operations**. ## D. Logistics Costs * **Improved Export Economics:** Logistics costs have normalized after prior freight spikes, enhancing competitiveness in overseas markets. * **DME Market Opportunity:** Significant demand potential in aerosol segment as a **greener alternative fuel**, positioning DME for strategic growth. --- # 6. Risks & Regulatory Factors ## A. Regulatory & Legal Developments * **LPG Blending Progress:** DME blending proposal under government review, with PESO clearances for cylinders and road tankers actively pursued. * **Antidumping Timeline:** Oral hearing completed for EDA case; new investigating officer assigned, with next hearing expected by month-end and results likely within a month. * **Targeted Competition:** **Dimethylformamide (DMF)** remains the sole product facing sustained competition, primarily from Chinese imports under fluctuating price conditions. ## B. Market Demand Dynamics * **Stable Core Demand:** Domestic demand for amines and intermediates remains resilient, with **80% to 90% of overall market demand stable** despite export volatility. * **Export Pressures:** Tariff impacts on end users contributing to mild volatility in international markets, though not materially disrupting overall performance. --- # 7. Guidance & Outlook ## A. Key Figures * **Expected Growth (FY26):** **15%** value and volume growth expected next financial year * EBITDA Margin Guidance: **20–22%** sustainable range (normal conditions) · **17.5–18%** minimum · **up to 24%** maximum potential * **Domestic Acetonitrile Demand Growth:** **7–8%** annual growth expected ## B. FY26 Growth Trajectory * **H2 Momentum Build:** Business progressing at measured pace, with second-half acceleration anticipated as new capacities ramp and core market demand strengthens. * **Stable Export Backlog:** Long-term supply agreements with U.S. and European customers expected to extend into next fiscal, supporting international revenue visibility. * **Growth Catalysts:** Expansion driven by R&D investments, cost optimization, and green chemistry initiatives underpinning future scalability. ## C. Margin Expectations * **Structural Margin Target:** Company targets 20–22% EBITDA margin as baseline under normal conditions, supported by product diversification and process innovation. * **Resilience Framework:** Disciplined capital allocation and optimal capacity utilization prioritized to defend margins amid competitive pressures. ## D. Demand Uptake Timing * **Near-Term Volume Headwinds:** New asset utilization may remain suboptimal due to global uncertainties and delayed scaling by domestic EV battery makers. * **EV Market Inflection Ahead:** Bulk demand from domestic EV battery segment expected between **December and April**, though timelines remain fluid. * **Export Recovery Expected:** Pharma and agro export weakness to reverse in coming quarters as end-market conditions improve. * **Domestic Solvent Demand Rising:** Acetonitrile poised for sustained 7–8% annual growth on back of pharma sector adoption.